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Abstract 
13α-Estrones are of great value owing to their potent multiple bioactivity, including anticancer 
activity. 3-OH or 3-OBn derivatives of 2- or 4-[(subst.) phenyl]-13α-estrone as potential 
antiproliferative agents have been synthesized via facile, microwave-induced, Pd-catalyzed 
Suzuki–Miyaura coupling. 2- or 4-Halogenated 13α-estrone derivatives have been reacted with 
(4-subst.)phenylboronic acids using Pd(PPh3)4 as catalyst. The nature of para substituents at 
the introduced phenyl group did not influence the outcome of couplings. Certain newly 
synthesized compounds displayed substantial antiproliferative action against human adherent 
cancer cell lines of gynecological origin. Important structure–activity relationships were 
revealed, which might be helpful in the design of potent and selective anticancer derivatives 
based on the hormonally inactive 13α-estrane core. 






The primary function of female sex hormones (estrogens) is to facilitate the development of 
female secondary sexual characteristics and to control the reproductive functions [1]. However, 
certain estrogens possess other biological activities, including anti-angiogenic, neuroprotective, 
anticancer effects and others [2]. Despite the known property of 17β-estradiol promoting cell 
proliferation, its derivatives might act as antiproliferative agents [3]. The major risk in the 
design of anticancer agents based on the estrane core is the potential hormonal side effect of 
the lead compound. One possibility for minimizing the undesirable estrogenic behavior is the 
transformation of natural estrogens into their core-modified analogs [4‒6]. 13α-Estrone (1a) is 
an epimer of natural estrone (Figure 1) [4]. The inversion of the configuration at C-13 results 
in a modified conformation, and that is why 13α-estrone and its 17-ol derivatives do not possess 
estrogenic behavior [7]. Considering that 13α-estrone (1a) is readily available in a single step 
from its natural counterpart, it might serve as a promising candidate for the design of anticancer 
compounds lacking hormonal action. We have demonstrated recently that this group of 
synthetic compounds offers great possibilities concerning bioactivity [8‒10]. It was shown that 
certain structurally different enzymes involved in estrogen biosynthesis [11,12] can be inhibited 
by 2- and/or 4-substitued 13α-estrone derivatives (Figure 2, compound I). The most potent 
inhibitors displayed IC50 values in ranges similar to those of their 13β counterparts. 
It should be highlighted that organic anion transporter protein OATP2B1, one of the key players 
in intestinal drug absorption and drug transport, can also be inhibited by 13α-estrone 
compounds (Figure 2, compound 3a) [13]. The observed inhibitory potencies are comparable 
to those of the best OATP2B1 inhibitors ever published.  
 
Figure 1.  
 
Not only enzyme inhibitory behavior, but the direct antiproliferative potential of certain 13α-
estrones have also been published by our group [14‒20]. Certain C-3-O and C-16 modified 
derivatives (Figure 2, compound II [14]) displayed outstanding cell growth-inhibitory action 
against a range of human adherent cancer cell lines. Investigations of the mechanism of action 
revealed that compound II indicated cell cycle blockade at the G2–M transition. Caspase 




Figure 2.  
 
The above-mentioned literature data suggest that 13α-estrones are of great value owing to their 
potent multiple bioactivity without estrogenic side effects. 
The Suzuki–Miyaura reaction is a palladium-catalyzed cross-coupling between organic boron 
compounds and organic halides [21,22]. It requires the addition of a base for activation of a 
boron reagent. The C(sp2)–C(sp2) coupling proceeds under mild conditions and tolerates a wide 
range of functional groups. This methodology is a very powerful tool for diaryl formation, 
including the synthesis of pharmaceuticals and complex natural products. 
Literature reveals the application of Suzuki–Miyaura coupling in the synthesis of estrone 
derivatives with diverse biological activities. C–C couplings on the estrane core were carried 
out mainly at C-2, C-3, C-4 or C-17 [23‒29]. Estrone derivatives such as aryl halides (at C-2 or 
C-4) or aryl or enol triflates (at C-3 or C-17) have been used. However, Ciana et al. developed 
a copper-catalyzed, site-selective C-H arylation methodology for the synthesis of 2-phenyl 
estrone derivatives [30]. Sato et al. synthesized estrone–isoquinoline hybrids as cortistatin 
analogs with substantial anti-angiogenic properties [23]. 17-Pyridyl estrones have been 
prepared as effective AKR1C3 inhibitors, which might be promising drug candidates in the 
treatment of endometriosis. Suzuki couplings at C-3 resulted in estrone derivatives as covalent 
17β-HSD1 inhibitors [24]. Langer et al. published recently the synthesis of 2- and/or 4-
arylestrones via C–C coupling. Certain 4-aryl regioisomers proved to be potent pancreatic 
lipase inhibitors [25]. Poirier et al. demonstrated that estrone derivatives bearing 2-
(subst.)phenyl ring possess substantial cytochrome P450 (CYP) 1B1 inhibitory activity [29]. 
Based on the above-mentioned literature results, here we intended to perform Suzuki–Miyaura 
couplings on the hormonally inactive 13α-estrane core. Regarding the promising biological 
properties of derivatives modified on ring A, C-2 and C-4 have been chosen as subjects for 
modifications. Our aim was to synthesize 3-hydroxy and 3-benzyloxy 2- or 4-(subst.)phenyl 
compounds. The determination of antiproliferative properties of the newly synthesized 13α-
estrone derivatives against a panel of five human adherent gynecological cancer cell lines 




Melting points (Mp) were determined with a Kofler hot-stage apparatus and are uncorrected. 
Elemental analyses were performed with a Perkin-Elmer CHN analyzer model 2400. Thin-layer 
chromatography: silica gel 60 F254; layer thickness 0.2 mm (Merck); eluents (ss): 30% ethyl 
acetate/70% hexane, detection with I2 or UV (365 nm) after spraying with 5% phosphomolybdic 
acid in 50% aqueous phosphoric acid and heating at 100–120 °C for 10 min. Flash 
chromatography: silica gel 60, 40–63 μm (Merck). Reactions under microwave irradiation were 
carried out with a CEM Corporation focused microwave system, Model Discover SP. The 
maximum power of irradiation was 200 W. 1H NMR spectra were recorded in DMSO-d6, 
CDCl3 solution with a Bruker DRX-500 instrument at 500 MHz, with Me4Si as internal 
standard. 13C NMR spectra were recorded with the same instrument at 125 MHz under the same 
conditions. Mass spectrometry: full scan mass spectra of the compounds were acquired in the 
range of 50 to 1000 m/z with a Finnigan TSQ-7000 triple quadrupole mass spectrometer 
(Finnigan-MAT, San Jose, CA) equipped with a Finnigan electrospray ionization source. 
Analyses were performed in positive ion mode using flow injection mass spectrometry with a 
mobile phase of 50% aqueous acetonitrile containing 0.1 v/v% formic acid. The flow rate was 
0.3 ml/min. Five µl aliquot of the samples were loaded into the flow. The ESI capillary was 
adjusted to 4.5 kV and N2 was used as a nebulizer gas. 
 
2.1.1. Reaction conditions for Suzuki-Miyaura coupling in 3-OH series 
2-Bromo-3-hydroxy-13α-estra-1,3,5(10)-trien-17-one (3a, 175 mg, 0.50 mmol) or 4-bromo-3-
hydroxy-13α-estra-1,3,5(10)-trien-17-one (6a, 175 mg, 0.50 mmol), Pd(PPh3)4 (58 mg, 0.050 
mmol, 0.1 equiv), K2CO3 (276 mg, 2.0 mmol, 4 equiv.), (4-subst.)phenylboronic acid (2 equiv.) 
and toluene (4 ml) were added under nitrogen atmosphere, in 10 mL Pyrex pressure vessels 
(CEM, Part #: 908035) with silicone cap (CEM, Part #: 909210) and the mixture was heated in 
a CEM microwave reactor at 100 °C for 30 min under stirring. The solvent was evaporated in 
vacuo. The residue was purified by flash chromatography with 10% ethyl acetate/ 90% hexane 
as eluent. 
2.1.1.1. 3-Hydroxy-2-phenyl-13α-estra-1,3,5(10)-trien-17-one (11a) 
Compound 11a was isolated as white crystals (165 mg, 95%). Mp.: 197−205 °C. Rf = 0.46. 
Anal calcd. for C24H26O2: C, 83.20; H, 7.56. Found: 83.28; H, 7.61. 
1H NMR (DMSO-d6)  
ppm: 0.96 (s, 3H, H-18), 2.72 (m, 2H, H-6), 6.59 (s, 1H, H-4), 7.08 (s, 1H, H-1), 7.25 (t, J=7.5 
Hz, 1H, H-4’), 7.34 (t, J=7.5 Hz, 2H, H-3’ and H-5’), 7.49 (d, J=7.1 Hz, 2H, H-2’ and H-6’), 
9.17 (s, 1H, 3-OH). 13C NMR (DMSO-d6)  ppm: 20.4 (CH2), 24.5 (C-18), 27.7 (CH2), 28.0 
(CH2), 29.2 (CH2), 31.6 (CH2), 32.8 (CH2), 40.6 (CH), 40.8 (CH), 48.5 (CH), 49.4 (C-13), 115.4 
(C-4), 125.2 (C-2), 126.1 (C-4’), 127.6 (C-1), 127.7 (2C, 2×CH), 128.9 (2C, 2×CH), 130.3 (C), 
136.8 (C), 138.8 (C), 151.8 (C-3), 220.6 (C-17). MSI m/z (%): 345 (100, [M-H]-). 
 
2.1.1.2. 3-Hydroxy-2-(4-chlorophenyl)-13α-estra-1,3,5(10)-trien-17-one (12a) 
Compound 12a was isolated as white crystals (180 mg, 94%). Mp.: 256−257 °C. Rf=0.43. Anal 
calcd. for C24H25ClO2: C, 75.68; H, 6.62. Found: 75.75; H, 6.53. 
1H NMR (DMSO-d6)  ppm: 
0.97 (s, 3H, H-18), 2.72 (m, 2H, H-6), 6.60 (s, 1H, H-4), 7.10 (s, 1H, H-1), 7.40 (d, J=8.6 Hz, 
2H, H-3’ and H-5’), 7.52 (d, J=8.6 Hz, 2H, H-2’ and H-6’), 9.31 (s, 1H, 3-OH). 13C NMR 
(DMSO-d6)  ppm: 20.4 (CH2), 24.5 (C-18), 27.7 (CH2), 28.0 (CH2), 29.2 (CH2), 31.5 (CH2), 
32.8 (CH2), 40.6 (CH), 40.8 (CH), 48.5 (CH), 49.4 (C-13), 115.5 (C-4), 123.8 (C-2), 127.4 (C-
1), 127.7 (2C, 2×CH), 130.5 (C), 130.6 (2C, 2×CH), 130.7 (C), 137.3(C), 137.6 (C), 151.8 (C-
3), 220.6 (C-17). MSI m/z (%): 379 (100, [M-H]-). 
 
2.1.1.3. 2-(4-tert-Butylphenyl)-3-hydroxy-13α-estra-1,3,5(10)-trien-17-one (13a) 
Compound 13a was isolated as white crystals (187 mg, 93%). Mp.: 238−240 °C. Rf=0.54. Anal 
calcd. for C28H34O2: C, 83.54; H, 8.51. Found: 83.61; H, 8.42.
 1H NMR (DMSO-d6)  ppm: 
0.96 (s, 3H, H-18), 1.29 (s, 9H, 4’-C(CH3)3), 2.71 (m, 2H, H-6), 6.58 (s, 1H, H-4), 7.07 (s, 1H, 
H-1), 7.25 (t, J=7.5 Hz, 1H, H-4’), 7.40 (2xd, J=8.5 Hz, 2x2H, H-2’,H-3’, H-5’ and H-6’), 9.14 
(s, 1H, 3-OH). 13C NMR (DMSO-d6)  ppm: 20.4 (CH2), 24.5 (C-18), 27.7 (CH2), 28.0 (CH2), 
29.2 (CH2), 31.0 (3C, 4’-C(CH3)3), 31.6 (CH2), 32.8 (CH2), 34.0 (4’-C(CH3)3, 40.6 (CH), 40.8 
(CH), 48.5 (CH), 49.4 (C-13), 115.4 (C-4), 124.5 (2C, 2×CH), 125.1 (C-2), 127.6 (C-1), 128.6 
(2C, 2×CH), 130.3 (C), 135.9 (C), 136.5 (C), 148.3 (C), 151.8 (C-3), 220.6 (C-17). MSI m/z 
(%): 401 (100, [M-H]-). 
 
2.1.1.4. 3-Hydroxy-4-phenyl-13α-estra-1,3,5(10)-trien-17-one (14a) 
Compound 14a was isolated as white crystals (163 mg, 94%). Mp.: 125−129 °C. Rf=0.56. Anal 
calcd. for C24H26O2: C, 83.20; H, 7.56. Found: 83.29; H, 7.50. 
1H NMR (DMSO-d6)  ppm: 
0.96 (s, 3H, H-18), 6.71 (d, J= 8.5 Hz, 1H, H-2), 7.08 (d, J= 8.5 Hz, 1H, H-1), 7.13 (t, J=7.4 
Hz, 2H, H-3’ and H-5’), 7.27 (t, J=7.4 Hz, 1H, H-4’), 7.36 (overlapping multiplets, 2H, H-2’ 
and H-6’), 8.82 (s, 1H, 3-OH). 13C NMR (DMSO-d6)  ppm: 20.9 (CH2), 24.9 (C-18), 28.3 
(CH2), 28.7 (CH2), 29.3 (CH2), 32.2 (CH2), 33.3 (CH2), 40.8 (CH), 41.6 (CH), 49.0 (CH), 49.9 
(C-13), 112.8 (C-2), 125.4 (CH), 126.2 (CH), 127.6(C), 127.8 (2C, 2×CH), 129.9 (2C, 2×CH), 
130.2 (C), 135.5 (C), 137.9 (C), 152.0 (C-3), 220.6 (C-17). MSI m/z (%): 345 (100, [M-H]-). 
 
2.1.1.5. 3-Hydroxy-4-(4-chlorophenyl)-13α-estra-1,3,5(10)-trien-17-one (15a) 
Compound 12a was isolated as white crystals (175 mg, 92%). Mp.: 71−78 °C. Rf=0.59. Anal 
calcd. for C24H25ClO2: C, 75.68; H, 6.62. Found: 75.74; H, 6.56. 
1H NMR (DMSO-d6)  ppm: 
0.96 (s, 3H, H-18), 6.71 (d, J= 8.5 Hz, 1H, H-2), 7.08 (d, J= 8.5 Hz, 1H, H-1), 7.10 (d, J=8.5 
Hz, 1H, H-1), 7.13 (m, 2H, H-3’ and H-5’), 7.41 (m, 2H, H-2’ and H-6’), 8.94 (s, 1H, 3-OH). 
13C NMR (DMSO-d6)  ppm: 20.3 (CH2), 24.4 (C-18), 27.7 (CH2), 28.2 (CH2), 28.7 (CH2), 
31.6 (CH2), 32.8 (CH2), 40.2 (CH), 41.0 (CH), 48.4 (CH), 49.3 (C-13), 112.8 (C-2), 125.8 (CH), 
126.3 (C), 127.8(2C, 2×CH), 130.2 (C), 131.0 (C), 131.8(CH), 131.9 (CH), 135.4 (C), 136.7 
(C), 152.0 (C-3), 220.6 (C-17). MSI m/z (%): 381 (100, [M+H]+). 
2.1.1.6. 4-(4-tert-Butylphenyl)-3-hydroxy-13α-estra-1,3,5(10)-trien-17-one (16a) 
Compound 13a was isolated as white crystals (183 mg, 91%). Mp.: 211−219°C. Rf=0.72. Anal 
calcd. for C28H34O2: C, 83.54; H, 8.51. Found: 83.60; H, 8.42. 
1H NMR (DMSO-d6)  ppm: 
0.96 (s, 3H, H-18), 1.31 (s, 9H, 4’-C(CH3)3), 6.69 (d, J= 8.5 Hz, 1H, H-2), 7.05 (m, 3H), 7.37 
(m, 2H), 8.80 (s, 1H, 3-OH). 13C NMR (DMSO-d6)  ppm: 20.9 (CH2), 24.9 (C-18), 28.3 (CH2), 
28.8 (CH2), 29.3 (CH2), 31.7 (3C, 4’-C(CH3)3), 32.2 (CH2), 33.3 (CH2), 34.6 (4’-C(CH3)3, 40.9 
(CH), 41.6 (CH), 49.0 (CH), 49.9 (C-13), 113,3 (C-2), 125.1 (2C, 2×CH), 125.8 (C-1), 128.0 
(C), 130.1 (2C, 2×CH), 130.7 (C), 135.4 (C), 136.3 (C), 148.7 (C), 152.7(C-3), 221.2 (C-17). 
MSI m/z (%): 403 (100, [M+H]+). 
 
2.1.2. Reaction conditions for Suzuki-Miyaura coupling in 3-OBn series 
3-Benzyloxy-2-bromo-13α-estra-1,3,5(10)-trien-17-one (3b, 220 mg, 0.50 mmol) or 3-
Benzyloxy-2-bromo-13α-estra-1,3,5(10)-trien-17-one (6b, 220 mg, 0.50 mmol), Pd(PPh3)4 (58 
mg, 0.050 mmol, 0.1 equiv), K2CO3 (276 mg, 2.0 mmol, 4 equiv.), (4-subst.)phenylboronic acid 
(2 equiv.) and toluene (4 ml) were added under nitrogen atmosphere, in 10 mL Pyrex pressure 
vessels (CEM, Part #: 908035) with silicone cap (CEM, Part #: 909210) and the mixture was 
heated in a CEM microwave reactor at 150 °C for 30 min under stirring. The solvent was 
evaporated in vacuo. The residue was purified by flash chromatography with 5% ethyl acetate/ 
95% hexane as eluent. 
2.1.2.1. 3-Benzyloxy-2-phenyl-13α-estra-1,3,5(10)-trien-17-one (11b) 
Compound 11b was isolated as white crystals (203 mg, 92%). Mp170−176 °C. Rf=0.70. Anal 
calcd. for C31H32O2: C, 85.28; H, 7.39. Found: 85.36; H, 7.30. 
1H NMR (C6D6)  ppm: 0.79 (s, 
3H, H-18), 2.55-2.66 (overlapping multiplets, 2H, H-6), 4.79 (s, 2H, 3-OCH2), 6.63 (s, 1H, H-
4), 7.01‒7.32 (overlapping multiplets, 9H), 7.21 (d, J=7.4 Hz, 2H), 13C NMR (CDCl3)  ppm: 
21.1 (CH2), 25.2 (C-18), 28.3 (CH2), 28.4 (CH2), 30.3 (CH2), 32.1 (CH2), 33.5 (CH2), 41.5 
(CH), 41.6 (CH), 49.4 (CH), 50.1 (C-13), 70.7 (OCH2), 113.6 (C-4), 126.7 (CH), 126.9 (2×CH), 
127.5 (CH), 127.9 (2×CH), 128.4 (2×CH), 128.7 (CH), 129.2 (2×CH), 129.6 (C), 132.6 (C), 
137.2 (C), 137.5 (C), 138.8 (C), 153.7 (C),  221.4 (C-17). MSI m/z (%): 437 (100, [M+H]+). 
 
2.1.2.2. 3-Benzyloxy-2-(4-chlorophenyl)-13α-estra-1,3,5(10)-trien-17-one (12b) 
Compound 12b was isolated as white crystals (221 mg, 94%). Mp.: 149−157°C. Rf=0.67. Anal 
calcd. for C31H31ClO2: C, 79.05; H, 6.63. Found: 79.12; H, 6.54. 
1H NMR (CDCl3)  ppm: 1.06 
(s, 3H, H-18), 2.86 (m, 2H, H-6), 5.02 (s, 2H, 3-OCH2), 6.74 (s, 1H, H-4), 7.21 (s, 1H, H-
1),7.28–7.34 (overlapping multiplets, 7H), 7.47 (m, 2H). 13C NMR (CDCl3)  ppm: 21.0 (CH2), 
25.1 (C-18), 28.2 (CH2), 28.3 (CH2), 30.3 (CH2), 32.0 (CH2), 33.4 (CH2), 41.4 (CH), 41.5 (CH), 
49.2 (CH), 50.1 (C-13), 70.5 (3-OCH2), 113.3 (C-4), 126.8 (2C, 2×CH), 127.6 (C-2), 127.7 
(CH), 128.0 (2C, 2×CH), 128.4 (3C, 3×CH), 130.8 (2C, 2×CH), 132.5 (2C, 2×C), 137.1 (2C, 
C), 137.6 (C), 153.4 (C-3), 221.5(C-17). MSI m/z (%): 472 (100, [M+H]+). 
 
 
2.1.2.3. 3-Benzyloxy-2-(4-tert-butylphenyl)-13α-estra-1,3,5(10)-trien-17-one (13b) 
Compound 13b was isolated as white crystals (227 mg, 92%). Mp.: 163−166°C. Rf=0. Anal 
calcd. for C35H40O2: C, 85.32; H, 8.18. Found: 85.40; H, 8.09. 
1H NMR (C6D6)  ppm: 0.79 (s, 
3H, H-18), 1.27 (s, 9H, 4’-C(CH3)3), 2.63 (m, 2H, H-6), 4.82 (s, 2H, 3-OCH2), 6.66 (s, 1H, H-
4), 7.03 (t, J= 7.3 Hz, 1H, H-4”), 7.11 (t, J= 7.6 Hz, 2H, H-3” and H-5”), 7.23 (d, J= 7.5 Hz, 
2H, H-2” and H-6”), 7.35(s, 1H, H-1), 7.41 (d, J= 8.4 Hz, 2H), 7.73 (d, J= 8.4 Hz, 2H). 13C 
NMR (CDCl3)  ppm: 21.0 (CH2), 25.1 (C-18), 28.2 (CH2), 28.3 (CH2), 30.2 (CH2), 31.4 (3C, 
4’-C(CH3)3), 32.1 (CH2), 33.4 (CH2), 34.5 (4’-C(CH3)3), 41.5 (2C, 2×CH), 49.2 (CH), 50.1 (C-
13), 70.6 (3-OCH2), 113.5 (C-4), 124.8 (2C, 2×CH), 126.8 (2C, 2×CH), 127.4 (CH), 128.3 (2C, 
2×CH), 128.6 (CH), 128.9 (C), 129.2 (2C, 2×CH), 132.4 (C), 135.6 (C), 136.8 (C), 137.5 (C), 
149.4 (C), 153.7 (C-3), 221.6 (C-17). MSI m/z (%): 493 (100, [M+H]+).  
 
2.1.2.4. 3-Benzyloxy-4-phenyl-13α-estra-1,3,5(10)-trien-17-one (14b) 
Compound 14b was isolated as white crystals (196 mg, 90%). Mp.: 58−60 °C. Rf=0.72. Anal 
calcd. for C31H32O2: C, 85.28; H, 7.39. Found: 85.35; H, 7.31. 
1H NMR (CDCl3)  ppm: 1.05 
(s, 3H, H-18), 4.95 (d, J= 3.9 Hz, 2H, 3-OCH2), 6.85 (d, J= 8.7 Hz, 1H, H-2), 7.08 (s, 1H, H-
1), 7.11 (m, 2H), 7.19–7.25 (overlapping multiplets, 6H), 7.33 (m, 1H), 7.41 (m, 1H). 13C NMR 
(CDCl3)  ppm: 21.1 (CH2), 25.1 (C-18), 28.4 (CH2), 28.5 (CH2), 28.9 (CH2), 32.1 (CH2), 33.4 
(CH2), 41.0 (CH), 41.8 (CH), 49.5 (CH), 50.1 (C-13), 70.5 (3-OCH2), 111.1 (C-2), 125.7 (CH), 
126.5 (2C, CH), 126.6 (CH), 127.3 (CH), 128.0 (2C, 2×CH), 128.2 (2C, 2×CH), 129.9 (CH), 
130.1 (CH), 131.2 (C), 133.1 (C), 136.6 (C), 137.6 (C), 137.8 (C), 153.9 (C-3), 221.4 (C-17). 
MSI m/z (%): 437 (100, [M+H]+). 
 
2.1.2.5. 3-Benzyloxy-4-(4-chlorophenyl)-13α-estra-1,3,5(10)-trien-17-one (15b) 
Compound 15b was isolated as white crystals (224 mg, 95%). Mp.: 67−69°C. Rf=0.74. Anal 
calcd. for C31H31ClO2: C, 79.05; H, 6.63. Found: 79.11; H, 6.56. 
1H NMR (CDCl3)  ppm: 1.04 
(s, 3H, H-18), 4.96 (d, J= 4.5 Hz, 2H, 3-OCH2), 6.83 (d, J= 8.7 Hz, 1H, H-2), 7.12 (m, 3H), 
7.11–7.25 (overlapping multiplets, 4H), 7.28 (m, 1H), 7.37 (m, 2H). 13C NMR (CDCl3)  ppm: 
21.0 (CH2), 25.0 (C-18), 28.3 (CH2), 28.4 (CH2), 29.0 (CH2), 32.1 (CH2), 33.4 (CH2), 40.9 
(CH), 41.7 (CH), 49.3 (CH), 50.1 (C-13), 70.2 (3-OCH2), 110.8 (C-2), 126.1 (CH), 126.5 (2C, 
2×CH), 127.4 (CH), 128.2 (2C, 2×CH), 128.3 (2C, 2×CH), 129.6 (C), 131.3 (CH), 131.5 (CH), 
132.5 (C), 133.0 (C), 136.2 (C), 136.5(C), 137.4 (C), 153.7 (C-3), 221.6 (C-17). MSI m/z (%): 
494 (100, [M+Na]+). 
 
2.1.2.6. 3-Benzyloxy-4-(4-tert-butylphenyl)-13α-estra-1,3,5(10)-trien-17-one (16b) 
Compound 16b was isolated as white crystals (222 mg, 90%). Mp.: 66−70°C. Rf=0.76. Anal 
calcd. for C35H40O2: C, 85.32; H, 8.18. Found: 85.41; H, 8.10. 
1H NMR (CDCl3)  ppm: 1.05 
(s, 3H, H-18), 1.38 (s, 9H, 4’-C(CH3)3), 4.93 (d, J= 6.5 Hz, 2H, 3-OCH2), 6.85 (d, J= 8.6 Hz, 
1H, H-2), 7.06 (m, 2H), 7.14 (m, 1H), 7.21 (m, 5H), 7.43 (m, 2H). 13C NMR (CDCl3)  ppm: 
21.0 (CH2), 25.0 (C-18), 28.4 (CH2), 28.5 (CH2), 29.0 (CH2), 31.4 (3C, 4’-C(CH3)3), 32.1 
(CH2), 33.4 (CH2), 34.5 (4’-C(CH3)3), 40.9 (CH), 41.8 (CH), 49.4 (CH), 50.1 (C-13), 70.5 (3-
OCH2), 111.3 (C-2), 124.8 (2C, 2×CH), 125.5 (CH), 126.5 (2C, 2×CH), 127.2 (CH), 128.1 (3C, 
3×CH), 129.4 (CH), 129.6 (CH), 131.3 (C), 134.6 (CH), 136.8 (C), 137.6 (C), 149.3 (C), 154.1 
(C-3), 221.7 (C-17). MSI m/z (%): 493 (100, [M+H]+). 
 
2.2. Determination of antiproliferative activities 
The antiproliferative properties of the newly synthesized compounds (3, 6 and 11‒16) were 
determined on a panel of human adherent cancer cell lines of gynecological origin. MCF-7 and 
MDA-MB-231 were isolated from breast cancers differing in biochemical background, while 
A2780 cells were isolated from ovarian cancer. Hela and SiHa are cervical cancer cell lines 
positive for HPV-18 and HPV-16, respectively. The cancer selectivity of compounds was tested 
on the non-cancerous mouse embryo fibroblast cell line NIH/3T3. All cell lines were purchased 
from European Collection of Cell Cultures (ECCAC, Salisbury, UK) exception for Siha 
(American Tissue Culture Collection, Manassas, VA, USA). Cells were cultivated in minimal 
essential medium supplemented with 10% fetal bovine serum, 1% non-essential amino acids 
and an antibiotic–antimycotic mixture. All media and supplements were obtained from Lonza 
Group Ltd., Basel, Switzerland. Near-confluent cancer cells were seeded onto a 96-well 
microplate (5000 cells/well) and, after overnight standing, 200 μL new medium, containing the 
tested compounds at 10 and 30 µM, was added. After incubation for 72 h at 37 °C in humidified 
air containing 5% CO2, the living cells were assayed by the addition of 20 μL of 5 mg/ml 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution. MTT was 
converted by intact mitochondrial reductase and precipitated as purple crystals during a 4-h 
contact period. The medium was next removed and the precipitated formazan crystals were 
dissolved in 100 μL of DMSO during a 60-min period of shaking at 37 оC. 
Finally, the reduced MTT was assayed at 545 nm, using a microplate reader utilizing wells with 
untreated cells serving as control [31]. In the case of the most active compounds (i.e. higher 
than 50% growth inhibition at 30 µM), the assays were repeated with a set of dilutions, 
sigmoidal dose–response curves were fitted to the determined data and the IC50 values (the 
concentration at which the extent of cell proliferation was half that of the untreated control) 
were calculated by means of GraphPad Prism 4.0 (GraphPad Software, San Diego, CA, USA). 
All in vitro experiments were carried out on two microplates with at least five parallel wells. 
Stock solutions of the tested substances (10 mM) were prepared in DMSO. The highest DMSO 
content of the medium (0.3%) did not have any substantial effect on cell proliferation. Cisplatin 
(Ebewe Pharma GmbH, Unterach, Austria) was used as positive control. 
 
  
3. Results and discussion 
The aromatic ring of 13α-estrone might readily be halogenated using different types of 
halogenating agents (Scheme 1, [8]). N-Halosuccinimides are suitable for the non-selective 
transformations of the phenolic moiety. Due to the activated behavior of ring A, and the ortho-
directing ability of the 3-OH group, a mixture of mono (2- or 4-substituted) and bis (2,4-
disubstituted) derivatives is formed. We demonstrated recently that the chemo- and 
regioselectivity of halogenations depend on the reagent and solvent applied [8]. Additionally, 
the nature and the size of the functional group at C-3 also influence the outcome of the reactions. 
Bis-2,4-derivates (beside the monosubstituted compounds) were formed exclusively when the 
starting compound possessed a phenolic OH group. In the case of methyl or benzyl ethers, only 
monosubstitutions occurred. We showed recently that 13α-estrone derivatives halogenated at 
ring A represent a very promising compound class with diverse biological activities. Enzymes 
17β-hydroxysteroid dehydrogenase 1 (17β-HSD1 and steroid sulfatase (STS) involved in 
estradiol biosynthesis could effectively be inhibited by certain halo derivatives. The 3-hydroxy-
2,4-bis-iodo derivative proved to be a dual inhibitor. The 2-bromo-3-hydroxy derivative should 
also be highlighted as it also displayed dual inhibitory properties against 17β-HSD1 enzyme 
and OATP2B1 transporter [8,13]. These favorable biological properties of compounds 
halogenated at ring A inspired us to perform further synthetic transformations using the 
compounds as aryl halide substrates. First, C(sp2)–C(sp) couplings were carried out in order to 
introduce large, but apolar groups onto the C-2 and C-4 positions. Sonogashira couplings with 
phenylacetylenes in the 3-OH series resulted in new compounds with substantial 17β-HSD1 
inhibitory potentials [9]. Products in the C-2 series, in turn, exhibited exclusive inhibitory 
potentials. These results suggest that the nature of the substituents at C-2, C-3 and/or C-4 exerts 
a great impact on the biological activity of 13α-estrone derivatives. 
 
Scheme 1.  
 
13α-Estrone was diversified at several sites, including different modifications at C-3 and/or in 
ring D with the aim of getting new compounds with potential antiproliferative behavior. It was 
shown that certain derivatives possess substantial cell growth-inhibitory potential against a 
number of human cancer cell lines of reproductive origin. We proved in many cases, that the 
presence of the apolar, bulky benzyl ether function at position C-3 is markedly beneficial 
concerning the antiproliferative potential [14,15,17]. 
It follows that 3-OH compounds might have increased enzyme inhibitory properties, whereas 
3-OBn derivatives might be promising cytostatic candidates. Nevertheless, it is worth 
evaluating new compounds in both series in order to get an insight into the correlation between 
activity and structure. 
Based on these findings, we selected 13α-estrone and its 3-O-benzyl counterpart as starting 
materials. The latter was synthesized in one step from estrone 3-benzyl ether in reaction with 
ortho-phenylenediamine in acetic acid. The Pd/C-catalyzed hydrogenolysis of the 3-benzyl-
13α-estrone product resulted in 13α-estrone in high yield. The halogenation of 3-OH and 3-
OBn substrates was achieved using N-halosuccinimides as described earlier [8]. Three different 
electrophile triggers (NCS, NBS or NIS) were used for the formation of aryl halides in order to 
investigate the influence of the nature of the halogen substituent on the C–C coupling reaction. 
The monosubstituted regioisomers (2a,b‒7a,b) served as starting compounds in Suzuki–




Phenylboronic acid and its two 4-substituted derivatives were chosen as coupling partners. 4-
Chlorophenylboronic acid seemed to be interesting due to the dual (negative inductive but 
positive mesomeric) electronic properties of chlorine. The large alkyl substituent in 4-tert-
butylphenylboronic acid might greatly influence the biological behavior as earlier established 
[15]. The reaction conditions applied here have been chosen according to our coupling methods 
described recently. Pd(PPh3)4 was used as catalyst, K2CO3 as base, and transformations have 
been carried out under microwave irradiation. First we performed C–C couplings of substrate 
2a,b‒7a,b with phenylboronic acid as a model reagent (Table 1). 2-Substituted regioisomers in 
the 3-OH series (3a, 4a) could efficiently be transformed (Table 1, Entries 2 and 3), except for 
the 2-chloro derivative (2a, Table 1, Entry 1). The latter could only be coupled using KOt-Bu 
as base at elevated temperature (150 °C) and longer microwave irradiation (60 min) (Table 1, 
Entry 13). These conditions proved to be applicable for the transformations of 4-chloro-3-
hydroxy (5a) and 3-benzyloxy-2- or 4-chloro derivatives (2b and 5b), too (Table 1, Entries 14‒
16). Concerning the reactions of bromo or iodo compounds (3, 4, 6, and 7), these substrates 
behaved in a similar way in these reactions (irrespective of the regioisomerism) (Table 1, 
Entries 2, 3, 5, 6, 8, 9, 11, 12). However, pronounced dehalogenation were observed in the case 
of iodo starting compounds (Table 1, Entries 3, 6, 9, 12). The nature of the substituent at C-3 
of 13α-estrane core influenced the outcome of couplings as established earlier in Hirao reactions 
[10]. Benzyl ethers needed harsher conditions (higher reaction temperature) than their hydroxy 




After establishing the appropriate reaction conditions (Table 1, Entries 2 and 8), 2- or 4-bromo-
3-OH and -3-OBn derivatives (3a,b or 6a,b) have been chosen for further transformations 
(Scheme 3). Suzuki–Miyaura couplings with subst.-phenylboronic acids afforded the desired 
products (11‒16) in excellent yields. 12 new arylated compounds have been synthesized. The 
structure of the newly synthesized 13α-estrone derivatives (11‒16) have been deduced from 1H 






The antiproliferative properties of the phenylated compounds (11a,b–16a,b) and their direct 
precursors (3a,b and 6a,b) were determined in vitro on a panel of human adherent breast (MCF-
7 and MDA-MB-231), cervical (HeLa and SiHa), and ovarian (A2780) cancer cell lines by 
means of MTT assay (Table 2). The two breast cancer cell lines involved in this study have 
different receptorial status [32‒34]. In contrast with the estrogen receptor positive MCF-7 cell 
line, MDA-MB-231 is a triple-negative cell line lacking all current clinically utilized 
pharmacological targets (receptors for estrogens, progesterone, and growth factor HER2/neu) 
for hormonal treatment. The triple-negative subtype of breast cancer, therefore, represents the 
portion of poorest prognosis among breast cancer cases [35]. The majority of cervical cancers 
is associated with human papilloma virus (HPV) infection [36,37]. Despite vaccination and 
screening, cervical cancer still causes high mortality rate in less developed countries. The 
utilized cell lines Hela and Siha represent HPV-18 and -16 positive cases, respectively. These 
two types of HPV are responsible for nearly 70% of cervical cancerous cases. Ovarian cancer 
is another common type of gynecological malignancies [38]. Its poor prognosis and high 
mortality rates arise from its high recurrence and acquired resistance to drug treatment. In order 
to investigate the antiproliferative properties of the synthesized compounds, the ovarian cancer 
cell line A2780 was also included. Evaluation of the promising antiproliferative compounds on 
the mentioned cell lines might initiate the development of new anticancer agents acting with 
better tolerance and higher effectiveness.  
Our data reveal conclusive structure–activity correlations concerning the bromo derivatives 
(3a,b and 6a,b, Table 2). The 3-OH compounds (3a and 6a) did not influence the cell growth 
of the tested tumor cells markedly. However, the 4-regioisomer 6b of benzyl ethers  exerted 
outstanding antiproliferative effect against all investigated cell lines. MCF-7 cells were the most 
sensitive to 6b with IC50 value in a submicromolar range. Compound 6b exerted somewhat 
lower inhibition against the cervical cell lines Hela and SiHa and triple negative breast cancer 
MDA-MB-231 with IC50 values in the low micromolar range. It is worth mentioning that 6b 
made a marked distinction between the two breast cancer cell lines, but not between the two 
cervical ones. The other 3-OBn regioisomer (3b) exhibited weak antiproliferative effect on the 
tested cell lines. As concerns compounds 3b and 6b, it should be highlighted, that substantial 
dependence of the regioselectivity on the antiproliferative potential was observed (in favor of 
the 4-regioisomer). The most relevant compounds were additionally tested against a mouse 
fibroblast cell line (NIH-3T3) in order to obtain preliminary data concerning the cancer 
selectivity of the elicited action. Compound 6b exerted only a limited (less than 50% inhibition 
even at 30 μM) action on this cell line, though the cells are highly sensitive to reference agent 
cisplatin. 
A comparison of the data for phenylated 3-OH (11a and 14a) and brominated 3-OH derivatives 
(3a and 6a) reveals that the presence of the phenyl ring instead of a bromine improved the 
antiproliferative activities only for the 2-regioisomer. The calculated IC50 values for compound 
11a were over 10 micromoles against MCF-7 and Hela, and the effects were weaker on the 
other cell lines including mouse fibroblasts. 11a proved to be more effective than 14a its 4-
counterpart. A moderate activity enhancement was observed in the case of 11b, which might 
be attributed to the presence of the 3-OBn function. Strikingly, the phenylated 4-regioisomer 
(14b) was less effective than its 2-counterpart (11b), and far less potent than its bromo 
derivative 6b. 
Setting against the results for phenyl and (subst.)phenyl derivatives demonstrates that the nature 
and the size of the ring A substituents greatly influence cytostatic properties. 
In general, compounds 13a and 16a bearing the 4"-t-Bu function seemed to be more potent than 
11a and 14a. The 3-OBn-4"-t-Bu derivatives (13b and 16b) displayed very weak growth 
inhibition, irrespective of the substitution pattern of ring A. 
Substantial enhancements in cytostatic potential were detected for the 2-(4"-chlorophenyl) 3-
OH compound (12a), except for A2780 cell line. 12a exerted pronounced effect on Hela cells 
with a 3.33 μM IC50 value, which is comparable with that of the most potent compound 6b. The 
next lowest IC50 value was obtained on MCF-7 for compound 12a, but it is far behind the 
corresponding data of 6b. It is important to note that essential differences arose here in the 
inhibitory values for the breast and cervical cell line pairs. This was not the case against Hela 
and SiHa concerning the results of 6b. The activity dependence of regioisomerism here was 
also significant, but the tendency was reversed to that in the case of 3b and 6b. Here the 2-
isomer (12a) was far more potent than its 4-counterpart (15a). The latter does not seem to be 
true for the (4"-chlorophenyl)-3-OBn compounds (12b and 15b), since 15b exerted more 
pronounced cell growth inhibitory effect against all cell lines. This is in a good agreement with 
the data obtained for 3b and 6b, but the potency of 15b is appreciably lower. 
Our 2-phenylethynyl derivative (I) synthesized recently was additionally included in the 
investigations. We were interested in comparison of the antiproliferative properties of 2-phenyl 
(11a) and 2-phenylethynyl (I) derivatives. The data in Table 2 reflect that the moderate activity 
of 11a decreased substantially, when a short linear linker (C≡C) is inserted between the two 
phenyl groups. Accordingly, the nature and geometry of the connection might substantially 





In conclusion, 2- or 4-[(subst.) phenyl]-13α-estrone derivatives have been synthesized via 
efficient, microwave-induced, Pd-catalyzed Suzuki–Miyaura coupling. Reactions of 2- or 4-
halogenated 13α-estrone derivatives with (4-subst.)phenylboronic acids using Pd(PPh3)4 as 
catalyst afforded the desired phenylated products in high yields. Certain effective 
submicromolar or low micromolar cell growth inhibitors (6b, 12a, and 13a) have been 
identified against human cancer cell lines of gynecological origin. The estrogen receptor 
positive MCF-7 and the HPV-18 positive Hela cancer cell lines were the most sensitive to the 
tested compounds. None of the most promising agents exerted substantial growth inhibitory 
action against fibroblasts indicating the cancer selectivity of the action. The most potent 
compound (6b) exerted outstanding submicromolar antitumoral activity against MCF-7 cell 
line and lower calculated IC50 values against all cell lines in comparison to those of reference 
agent cisplatin. The most effective phenylated compound (12a) exerted selective low 
micromolar activities against two cell lines (MCF-7 and Hela). Compounds 6b and 12a behaved 
similarly as concerns breast cell lines MCF-7 and MDA-MB-231. However, 12a differentiated 
between the two cervical cell lines Hela and SiHa. Accordingly, ring A substitution of 13α-
estrone derivatives leads to effective antitumoral compounds. The substitution pattern of the 
aromatic ring influences cell growth inhibition markedly. The promising inhibitory data 
motivate further structural modifications in ring A of 13α-estrone, and additional investigations 
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Legends for Tables, Figures and Schemes 
Table 1: Effect of reaction conditions on C–C coupling of halogenated 13α-estrones (2a,b‒
7a,b) with phenylboronic acid in toluene catalyzed by Pd(PPh3)4
1 
Table 2: Antiproliferative properties of the synthesized compounds 
Figure 1: The structure of 13α-estrone (1a) and its 3-benzyl ether (1b) 
Figure 2: Potent, biologically active 13α-estrone derivatives (I, 3a and II)  
Scheme 1: Synthesis of ring A halogenated 13α-estrone derivatives 
Scheme 2: Suzuki-Miyaura couplings with phenylboronic acid as model reagent 
Scheme 3: Suzuki–Miyaura couplings of 2- or 4-bromo-13α-estrones. Reactions were 
performed on a 0.50 mmol scale with 2 equiv of subst.-phenylboronic acid, 0.1 equiv. 





1Aryl halide (0.50 mmol), Pd(PPh3)4 (0.1 equiv), K2CO3 (4 equiv.), (4-subst.)phenylboronic 
acid (2 equiv.), toluene, N2 atmosphere. 
2Flash chromatography yield obtained under microwave irradiation. 
 
 
Table 2:  
1 Mean value from two independent measurements with five parallel wells; standard deviation 
<20%. n.t.: not tested. 












1 2a K2CO3 100 30 0 
2 3a K2CO3 100 30 
11a + 1a 
(95 + 2) 
3 4a K2CO3 100 30 
11a + 1a 
(83 + 12) 
4 5a K2CO3 100 30 0 
5 6a K2CO3 100 30 
14a + 1a 
(94 + 3) 
6 7a K2CO3 100 30 
14a + 1a 
(80 + 15) 
7 2b K2CO3 150 30 0 
8 3b K2CO3 150 30 
11b + 1b 
(92 + 4) 
9 4b K2CO3 150 30 
11b + 1b 
(82 + 7) 
10 5b K2CO3 150 30 0 
11 6b K2CO3 150 30 
14b + 1b 
(90 + 4) 
12 7b K2CO3 150 30 
14b + 1b 
(81 + 10) 
13 2a KOt-Bu 150 60 
11a 
(43) 
14 5a KOt-Bu 150 60 
14a 
(51) 
15 2b KOt-Bu 150 60 
11b 
(41) 
16 5b KOt-Bu 150 60 14b 
(40) 
 






Inhibition (%) ± SEM 
[Calculated IC50]1 
MCF-7 MDA-MB-231 HeLa SiHa A2780 NIH-3T3 
 
3a 
10 - - - - - 
n.t. 
30 24.26 ± 0.76 22.85 ± 1.97 32.26 ± 0.52 20.72 ± 3.56 - 
 
6a 
10 - - - - - 
n.t. 
30 51.92 ± 1.61 42.09 ± 1.31 54.81 ± 1.14 - 44.21 ± 1.09 
 
3b 
10 - - - - - 
n.t. 
30 - - 48.57 ± 1.40 - - 
 
6b 
10 76.67 ± 0.30 54.41 ± 0.88 60.23 ± 0.42 59.04 ± 1.51 47.78 ± 2.10 30.59 ± 0.47 
30 
79.45 ± 0.85 
(0.52) 
62.36 ± 0.67 
(3.91) 
68.16 ± 0.62 
(2.85) 
63.04 ± 0.41 
(2.74) 
54.75 ± 1.06 29.55 ± 0.36 
 
11a 
10 44.72 ± 0.73 31.50 ± 1.77 36.82 ± 0.98 33.49 ± 0.90 35.73 ± 1.21 35.48 ± 1.33 
30 
71.54 ± 0.40 
(13.12) 
48.97 ± 0.42 
63.67 ± 0.30 
(17.06) 
54.36 ± 0.37 45.89 ± 0.96 40.04 ± 1.48 
 
14a 
10 - - - - - 
n.t. 
30 - - 27.29 ± 1.02 - - 
 
11b 
10 32.11 ± 1.90 - 51.26 ± 0.20 25.45 ± 2.09 25.44 ± 1.06 - 
30 
74.50 ± 1.16 
(16.87) 
76.16 ± 1.05 
(18.92) 
75.53 ± 0.18 
(8.98) 
70.06 ± 1.48 
(18.56) 





10 - - - - - 
n.t. 
30 27.35 ± 1.36 - - - 27.14 ± 0.94 
 
13a 
10 47.97 ± 0.98 42.24 ± 1.02 66.29 ± 0.87 44.03 ± 1.15 52.46 ± 0.20 45.30 ± 2.71 
30 
66.68 ± 0.71 
(12.82) 
53.23 ± 0.35 
77.67 ± 0.42 
(6.69) 
51.95 ± 0.78 
68.13 ± 0.55 
(9.41) 
51.68 ± 1.96 
 
16a 
10 - - 38.70 ± 1.67 - 35.83 ± 1.92 - 
30 
96.93 ± 0.33 
(15.73) 
91.02 ± 0.59 
(17.19) 
97.96 ± 0.15 
(11.19) 
92.43 ± 0.88 
(16.90) 





10 - - 24.51 ± 1.62 - - 
n.t. 




10 - - - - - 
n.t. 
30 32.81 ± 1.33 - - - 24.65 ± 2.81 
12a 10 53.41 ± 0.23 25.95 ± 0.43 73.65 ± 0.22 50.85 ± 0.30 24.97 ± 0.52 26.47 ± 1.33 
 
30 
59.51 ± 0.22 
(5.33) 
61.92 ± 0.67 
(18.32) 
75.46 ± 0.81 
(3.33) 
53.45 ± 0.95 33.61 ± 0.74 28.17 ± 0.25 
 
15a 
10 - - - - 20.20 ± 1.13 - 
30 
88.41 ± 1.35 
(19.76) 
52.83 ± 1.31 
 
80.24 ± 0.21 
(17.91) 
72.66 ± 1.09 
(21.19) 
82.92 ± 0.45 
(14.97) 
20.9 ± 0.42 
 
12b 
10 - - - - - 
n.t. 




10 48.56 ± 0.32 - 47.73 ± 1.65 - - - 
30 
77.13 ± 0.40 
(9.95) 
33.67 ± 1.39 64.12 ± 2.00 62.32 ± 0.94 55.04 ± 0.61 - 
 
I 
10 23.51 ± 1.95 - - - - 
n.t. 
30 
69.00 ± 0.32 
(21.51) 
29.66 ± 0.59 59.89 ± 1.16 46.18 ± 0.14 




10 53.03 ± 2.29 - 42.61 ± 2.33 88.64 ± 0.50 83.57 ± 1.21 91.80 ± 0.39 
30 
86.90 ± 1.22 
(5.78) 
71.47 ± 1.20 
(19.13) 
99.93 ± 0.26 
(12.43) 
90.18 ± 1.78 
(7.84) 
95.02 ± 0.28 
(1.30) 































IC50 = 0.15 M (17-HSD1) IC50 = 0.54 M (OATP2B1)






















2 X = Cl
3 X = Br













5 X = Cl
6 X = Br
7 X = I  
Scheme 3 
 
 
 
